Expertise: Maurice Boissinot is a microbiologist having experience working in industry as well as in the academic world. He obtained a PhD in microbiology-immunology from Université Laval in 1989. He received his post-doctoral training at the Scripps Research Institute (the largest private research institute of the early 1990s) in San Diego and at Chiron Corporation (one of the top 3 biotech company at the time) in the San Francisco bay area. He came back to Université Laval as associated granting professor and was member of the Canadian Bacterial Diseases Network. From 1996 to 1998, he acted as scientific director of BCM Oncologia a small biotech company from Quebec City. Since 1998, he is project leader in the molecular diagnostic group of professor Michel G. Bergeron at the Infectious Diseases Research Center (CRI) of Université Laval, where he is working on the development of rapid tests for the detection and identification of pathogenic micro-organisms. He is also curator of the strain collection of CRI (CCRI: more than 20 000 strains representing most human bacterial pathogens and several human viruses), manages sequences/specimens/strain databases, oversees the creation of new bioinformatics tools, and is involved in the management of the group’s IP portfolio. He was a member of the team that developed the first two real-time PCR tests to be approved by the Food and Drug Administration (FDA). He was responsible to develop Bacillus anthracis and SARS-CoV rapid detection tests for Canadian military and civilian emergency responses programs. He also organized expeditions of the Atlantis mobile laboratory in northern Quebec and in the Caribbean. He is an author on over 85 scientific publications covering disciplines such as medical and environmental microbiology, chemistry, microfluidics, nanotechnology, and physics. He is also inventor on numerous patents in the field of molecular diagnostics. He described 8 novel bacterial species. He was member of the board of the Quebec city molecular diagnostics company GenePOC Inc. from 2009 to 2014. Member of the Advisory Committee on the Human Pathogens and Toxins Act (AC-HPTA) for the Public Health Agency of Canada (2014-2020). He is currently the project manager on a 5.2M$ translational research program funded by the Quebec Ministry of Economy and Innovation and GenePOC inc. In charge of aim 3a.